LeBoff MS, Greenspan SL, Insogna KL et al (2022) The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049–2102. https://doi.org/10.1007/s00198-021-05900-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qaseem A, Forciea MA, McLean RM et al (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:818–839. https://doi.org/10.7326/M15-1361

Article  PubMed  Google Scholar 

Lacey DL, Boyle WJ, Simonet WS et al (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401–419. https://doi.org/10.1038/nrd3705

Article  CAS  PubMed  Google Scholar 

Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045. https://doi.org/10.4065/83.9.1032

Article  CAS  PubMed  Google Scholar 

Wu J, Zhang Q, Yan G, Jin X (2018) Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J Orthop Surg Res 13:194. https://doi.org/10.1186/s13018-018-0865-3

Article  PubMed  PubMed Central  Google Scholar 

Lyu H, Jundi B, Xu C et al (2019) Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 104:1753–1765. https://doi.org/10.1210/jc.2018-02236

Article  PubMed  Google Scholar 

Lin T, Wang C, Cai XZ et al (2012) Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 66:399–408. https://doi.org/10.1111/j.1742-1241.2011.02806.x

Article  CAS  PubMed  Google Scholar 

Wang WY, Chen LH, Ma WJ, You RX (2023) Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: A network meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci 27:8253–68. https://doi.org/10.26355/eurrev_202309_33586

Article  PubMed  Google Scholar 

Migliorini F, Maffulli N, Colarossi G et al (2021) Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res 16:533. https://doi.org/10.1186/s13018-021-02678-x

Article  PubMed  PubMed Central  Google Scholar 

Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ (2014) Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. J Clin Endocrinol Metab 99:3746–3755. https://doi.org/10.1210/jc.2013-3795

Article  CAS  PubMed  Google Scholar 

Silva-Fernández L, Rosario MP, Martínez-López JA, Carmona L, Loza E (2013) Denosumab for the treatment of osteoporosis: a systematic literature review. Reumatol Clin 9:42–52. https://doi.org/10.1016/j.reuma.2012.06.007

Article  PubMed  Google Scholar 

Yang L, Kang N, Yang JC et al (2019) Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis. Eur Rev Med Pharmacol Sci 23:2640–68. https://doi.org/10.26355/eurrev_201903_17414

Article  CAS  PubMed  Google Scholar 

Beaudoin C, Jean S, Bessette L et al (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27:2835–2844. https://doi.org/10.1007/s00198-016-3607-6

Article  CAS  PubMed  Google Scholar 

Seeto AH, Abrahamsen B, Ebeling PR, Rodríguez AJ (2021) Cardiovascular safety of denosumab across multiple indications: A systematic review and meta-analysis of randomized trials. J Bone Miner Res 36:24–40. https://doi.org/10.1002/jbmr.4157

Article  CAS  PubMed  Google Scholar 

Catton B, Surangiwala S, Towheed T (2021) Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials. Int J Rheum Dis 24:869–879. https://doi.org/10.1111/1756-185X.14101

Article  CAS  PubMed  Google Scholar 

Tan X, Wen F, Yang W et al (2019) Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). Menopause 26(8):929–939. https://doi.org/10.1097/GME.0000000000001321

Article  PubMed  Google Scholar 

Freemantle N, Cooper C, Diez-Perez A et al (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24:209–217. https://doi.org/10.1007/s00198-012-2068-9

Article  CAS  PubMed  Google Scholar 

Barrionuevo P, Kapoor E, Asi N et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623–1630. https://doi.org/10.1210/jc.2019-00192

Article  PubMed  Google Scholar 

Albert SG, Reddy S (2017) Clinical evaluation of cost efficacy of drugs for treatment of osteoporosis: a meta-analysis. Endocr Pract 23:841–856. https://doi.org/10.4158/EP161678.RA

Article  PubMed  Google Scholar 

Li P, Wu X, Li Y, Huang J (2022) Denosumab versus bisphosphonates for the prevention of the vertebral fractures in men with osteoporosis: an updated network meta-analysis. Clin Invest Med 45:E14-22. https://doi.org/10.25011/cim.v45i3.38875

Article  CAS  PubMed  Google Scholar 

Murad MH, Drake MT, Mullan RJ et al (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1871–1880. https://doi.org/10.1210/jc.2011-3060

Article  CAS  PubMed  Google Scholar 

Migliore A, Broccoli S, Massafra U, Cassol M, Frediani B (2013) Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. Eur Rev Med Pharmacol Sci 17:658–667

CAS  PubMed  Google Scholar 

Ayers C, Kansagara D, Lazur B et al (2023) Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 176:182–195. https://doi.org/10.7326/M22-0684

Article  PubMed  Google Scholar 

Ding LL, Wen F, Wang H et al (2020) Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data. Osteoporos Int 31:961–971. https://doi.org/10.1007/s00198-019-05183-4

Article  CAS  PubMed  Google Scholar 

Yang XC, Deng ZH, Wen T et al (2016) Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem 40:781–795. https://doi.org/10.1159/000453138

Article  CAS  PubMed  Google Scholar 

Jin YZ, Lee JH, Xu B, Cho M (2019) Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 20:399. https://doi.org/10.1186/s12891-019-2769-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nayak S, Greenspan SL (2017) Osteoporosis treatment efficacy for men: a systematic review and meta-Analysis. J Am Geriatr Soc 65:490–495. https://doi.org/10.1111/jgs.14668

Article  PubMed  Google Scholar 

Zhang L, Pang Y, Shi Y et al (2015) Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause 22:1021–1025. https://doi.org/10.1097/GME.0000000000000466

Article  PubMed  Google Scholar